RRx-001 protects against cisplatin-induced toxicities

RRx-001, A novel dinitroazetidine radiosensitizer

(2016) Bryan Oronsky et al.   INVESTIGATIONAL NEW DRUGS

A look inside the mechanistic black box: Are red blood cells the critical effectors of RRx-001 cytotoxicity?

(2016) Pedro Cabrales et al.   MEDICAL ONCOLOGY

Concurrent whole brain radiotherapy and RRx-001 for melanoma brain metastases

(2016) Michelle M. Kim et al.   NEURO-ONCOLOGY

Whole Brain Radiotherapy and RRx-001: Two Partial Responses in Radioresistant Melanoma Brain Metastases from a Phase I/II Clinical Trial

(2016) Michelle M. Kim et al.   Translational Oncology

Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies

(2016) Corey A. Carter et al.   Oncotarget

Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study

(2015) Tony Reid et al.   LANCET ONCOLOGY

Epigenetic effects of RRx-001: a possible unifying mechanism of anticancer activity

(2015) Hongjuan Zhao et al.   Oncotarget

Nrf2 activity as a potential biomarker for the pan-epigenetic anticancer agent, RRx-001

(2015) Shoucheng Ning et al.   Oncotarget

NO to cancer: The complex and multifaceted role of nitric oxide and the epigenetic nitric oxide donor, RRx-001

(2015) Jan Scicinski et al.   Redox Biology

Cisplatin in cancer therapy: Molecular mechanisms of action

(2014) Shaloam Dasari et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Rewriting the Epigenetic Code for Tumor Resensitization: A Review

(2014) Bryan Oronsky et al.   Translational Oncology

Dinitroazetidines Are a Novel Class of Anticancer Agents and Hypoxia-Activated Radiation Sensitizers Developed from Highly Energetic Materials

(2012) S. Ning et al.   CANCER RESEARCH

Cisplatin Cytotoxicity: DNA and Plasma Membrane Targets

(2008) Amelie Rebillard et al.   CURRENT MEDICINAL CHEMISTRY